Evaluate the efficacy of various treatments for metastatic uveal melanoma (mUM).
Key Findings:
Liver-directed therapy combined with immune checkpoint inhibitors (ICIs) showed the best efficacy for OS and PFS, indicating a significant advancement in treatment options.
Tebentafusp had the second-best OS but the worst PFS among treatments, highlighting its limitations.
ICIs were inferior to tebentafusp for OS but superior for PFS, suggesting a nuanced understanding of treatment effectiveness.
Liver-directed therapy demonstrated more favorable outcomes compared to conventional systemic chemotherapy, reinforcing its importance in treatment strategies.
Interpretation:
Liver-directed therapy combined with ICIs is the most effective treatment for mUM, while tebentafusp offers a significant but limited benefit.
Limitations:
Emerging immunotherapies and novel targeted agents could not be included due to lack of comparative trials.
Geographical variations in treatment practices may affect generalizability, and potential biases in the studies reviewed should be considered.
Conclusion:
Liver-directed therapy combined with ICIs is superior for extending OS and PFS in mUM. Future studies should include emerging therapies to further enhance treatment options.
